Cadillac Formula 1 Team has appointed Viatris as its Official Global Pharmaceutical Partner under a multi-year agreement beginning with the 2027 Formula 1 season.
The agreement gives the US-headquartered healthcare company a global association with Cadillac’s second season in Formula 1. The announcement describes a brand and audience platform rather than a medical-supply or technical programme; neither party identified products, services or healthcare provision for team personnel.
Cadillac says the partnership forms part of a longer-term commercial programme around its growing US and international fan base. Viatris says it intends to use the relationship to introduce its corporate brand to new audiences. Those are the companies’ stated objectives, not measured outcomes.
Excel Sports Management, Cadillac’s agency of record, supported the partnership discussions. The disclosure identifies an agency role but does not publish its fee, mandate or continuing activation responsibilities.
The parties did not disclose the agreement’s financial value, exact end date, branding inventory, hospitality allocation, campaign budget or performance targets. MRI has therefore reported the confirmed category rights and start season without estimating the deal’s scale.
MRI compared the Viatris source and canonical URL, headline, Cadillac and Viatris entities, partner category, 2027 start and 16 November event date against existing MRI news. Earlier Cadillac coverage concerns different partners, facilities and appointments; no exact or near-duplicate article was found.
The article is linked to Cadillac Formula 1 Team’s exact MRI profile and uses the approved logo already held there. MRI found no exact Viatris directory profile and did not attach an unrelated record. No feature image was reused because first-party publication permission was not established.